Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411237 | 0.86 | SLC7A5 (0.38) | AAK1SLC7A5MEN1KMT2A | |
| SCHEMBL31411233 | 0.86 | SLC7A5 (0.38) | AAK1SLC7A5MEN1KMT2A | |
| SCHEMBL25321590 | 0.86 | DPP4 (0.43) | DPP4SLC7A5 | |
| SCHEMBL23544353 | 0.86 | SLC7A5 (0.38) | AAK1SLC7A5MEN1KMT2A | |
| SCHEMBL28761485 | 0.86 | AAK1 (0.41) | AAK1DPP4DGAT1USP30BMP1 | |
| SCHEMBL19428705 | 0.85 | AAK1 (0.46) | AAK1DPP4USP30BMP1APLNR | |
| SCHEMBL16064075 | 0.85 | MAPT (0.41) | DPP4DGAT1BMP1MEN1KMT2A | |
| SCHEMBL27665844 | 0.84 | AAK1 (0.40) | AAK1DPP4DGAT1USP30BMP1 | |
| SCHEMBL27147765 | 0.84 | DGAT1 (0.40) | DGAT1BMP1MEN1KMT2APDPK1 | |
| SCHEMBL21029380 | 0.83 | KIF11 (0.42) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301286-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301286-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | AAK1 956/4885DPP4 265/4885DGAT1 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.